Company intelligence / Profile preview

Haining Health-coming Biotech

Haining, Zhejiang Sheng, China

Ownership: Private
Development stage: Other

Overview

The company’s lead asset, XH1, has been evaluated in a Phase 2 clinical trial for metastatic non-small cell lung cancer patients who failed first-line chemotherapy. The study compared docetaxel with or without XH1. No published results are available as of June 2025.

Therapeutic areas: Oncology
Modalities: Other (Traditional Chinese Medicine-based therapy)
Industry: Biotech

Drug pipeline

1 asset

XH1

Beyond the preview

Go deeper on Haining Health-coming Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Haining Health-coming Biotech.